<DOC>
	<DOCNO>NCT00448838</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may also stop growth pancreatic cancer block blood flow tumor . Drugs use chemotherapy , gemcitabine oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving cetuximab together combination chemotherapy may kill tumor cell . PURPOSE : This clinical trial study well give cetuximab together gemcitabine oxaliplatin work treat patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Cetuximab , Gemcitabine , Oxaliplatin Treating Patients With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival patient locally advance metastatic pancreatic cancer treat cetuximab , gemcitabine hydrochloride , oxaliplatin . Secondary - Determine complete response partial response patient treat regimen . - Determine time progression patient treat regimen . - Determine duration response patient treat regimen . - Determine survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This nonrandomized , open-label , pilot study . Patients receive cetuximab IV 1-2 hour day 1 8 , gemcitabine hydrochloride IV 100 minute day 1 , oxaliplatin IV 2-4 hour day 2 . Treatment repeat every 14 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm pancreatic cancer Locally advance metastatic disease No active CNS metastases Patients stable CNS disease , undergone radiotherapy within past 4 week stable dose corticosteroid &gt; 3 week , eligible PATIENT CHARACTERISTICS : ECOG performance status 01 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 mg/dL Alkaline phosphatase ≤ 3 time upper limit normal ( ULN ) ( 5 time ULN know hepatic metastasis ) AST ALT ≤ 3 time ULN ( 5 time ULN know hepatic metastasis ) Creatinine ≤ 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 90 day completion study treatment No significant history uncontrolled cardiac disease , include follow : Uncontrolled hypertension Unstable angina Myocardial infarction within past 6 month Uncontrolled congestive heart failure Cardiomyopathy decrease ejection fraction No prior severe infusion reaction monoclonal antibody No active infection fever ≥ 38.5°C within past 3 day No known hypersensitivity component gemcitabine hydrochloride , oxaliplatin , monoclonal antibody No peripheral neuropathy ≥ grade 2 No know HIV positivity No hepatitis B C infection ( active , previously treat , ) No medical condition , include mental illness substance abuse , would preclude study compliance PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy , include surgery More 30 day since prior investigational therapy More 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow More 30 day since prior chemotherapy No prior chemotherapy metastatic pancreatic cancer Prior fluoropyrimidine radiosensitizer allow Prior gemcitabine hydrochloride adjuvant set allow No prior therapy specifically directly target epidermal growth factor receptor ( EGFR ) pathway No prior allogeneic transplantation No concurrent investigational therapy , chemotherapy , systemic antineoplastic therapy No concurrent treatment target EGFR No concurrent monoclonal antibody therapy No concurrent radiotherapy except local control bone pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
</DOC>